Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 22 Oct 2026 | 10:45 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
BILASTINE,MONTELUKAST
Last updated on 22 Oct 2026 | 10:45 AM (IST)
BILASTINE,MONTELUKAST
Molecule Overview
This is a fixed combination of bilastine (a second-generation, non-sedating antihistamine) and montelukast (a leukotriene receptor antagonist), used together to treat allergic conditions, particularly allergic rhinitis, especially when accompanied by asthma-like symptoms or where a single agent alone hasn't provided adequate relief. It is a prescription-only medicine.
Medical Classification
Therapeutic Class: Anti-allergic combination therapy.
Pharmacological Class: Second-generation H1 antihistamine (bilastine) plus leukotriene receptor antagonist (montelukast).
Drug Family: Combination allergy/asthma-adjacent therapy.
ATC Classification: Not applicable as a single combined code; bilastine alone carries R06AX29, montelukast R03DC03.
Conditions Treated
Approved/established use: Allergic rhinitis (seasonal and perennial) and urticaria (hives), particularly when accompanied by nasal congestion or asthma-related symptoms where the added anti-leukotriene effect of montelukast may provide additional benefit.
Commonly used for: Patients with moderate to severe allergic rhinitis symptoms, especially those with coexisting mild asthma or exercise-induced bronchoconstriction, where combining an antihistamine with a leukotriene receptor antagonist is considered appropriate.
Off-label use (only under medical guidance): Not typically used off-label; use follows standard allergic rhinitis/asthma-adjacent management guidance.
Available Strengths & Dosage Forms
Oral tablets: commonly bilastine 20 mg combined with montelukast 10 mg.
How the Molecule Works
Bilastine blocks histamine H1 receptors, reducing the sneezing, itching, runny nose, and hives caused by histamine release during an allergic reaction, without significant sedation at standard doses. Montelukast blocks leukotriene receptors, reducing the effects of leukotrienes, separate inflammatory chemical messengers involved in both allergic airway inflammation and, to some extent, nasal congestion. Combining the two addresses allergic symptoms through two distinct inflammatory pathways.
Dosage & Administration
Standard dose: One tablet (bilastine 20 mg/montelukast 10 mg) taken orally once daily, generally at the same time each day.
Condition-wise dose: Duration of use is guided by the treating doctor based on the specific allergic condition (seasonal vs. perennial rhinitis) and symptom pattern.
Route: Oral, taken on an empty stomach (at least 1 hour before or 2 hours after a meal) for bilastine's optimal absorption, or as directed by the specific product's label.
Missed dose: Take as soon as remembered unless close to the next dose; don't double up.
Overdose: May cause increased side effects such as headache or mild sedation; requires medical attention if significantly exceeded.
Side Effects
Common: Headache, and, less commonly than with older antihistamines, mild drowsiness.
Serious: Rarely, mood or behaviour changes (including sleep disturbances, anxiety, or, uncommonly, more significant neuropsychiatric effects) have been reported with montelukast; a severe allergic reaction is also possible, though uncommon.
Emergency symptoms: Signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing), or any new or worsening mood/behaviour changes, particularly agitation or suicidal thoughts, which should be reported to a doctor promptly.
Recovery advice: Bilastine is generally well tolerated with minimal sedation; any new mood or behavioural symptoms linked to montelukast should be discussed with the prescribing doctor rather than continuing without review.
Warnings & Precautions
Pregnancy: Used only if clearly needed, under medical guidance.
Breastfeeding: Used with medical guidance.
Liver disease: Used with caution; montelukast in particular is metabolised by the liver.
Kidney disease: Used with routine monitoring; bilastine dose adjustment may be needed in significant impairment.
Elderly: Used with routine monitoring; no specific major dose adjustment beyond general precautions.
Children: Not typically used as this specific fixed combination in children; individual components have their own separate pediatric dosing and age-appropriateness.
Drug Interactions
Ketoconazole, erythromycin, and other CYP3A4/P-glycoprotein-affecting drugs: can alter bilastine levels; caution advised.
Food, particularly fruit juices (grapefruit, orange, apple): can significantly reduce bilastine absorption, which is why it's recommended to be taken away from meals.
Phenobarbital, rifampin: can reduce montelukast levels by inducing its metabolism.
Other sedating medicines: caution advised, given mild potential for additive sedation, though bilastine itself is largely non-sedating at standard doses.
Monitoring Requirements
Assessment of allergic symptom control (nasal congestion, sneezing, hives) over time.
Monitoring for mood or behavioural changes, particularly early in treatment, given the montelukast component's recognised (though uncommon) neuropsychiatric effect profile.
Liver function review if montelukast is used long-term and there are specific risk factors.
Alternative Molecules
Other second-generation antihistamines (e.g., cetirizine, fexofenadine, levocetirizine) used alone or with montelukast; Bilastine alone, or montelukast alone, depending on symptom profile.
Combination Therapies
This is itself a fixed combination; sometimes used alongside intranasal corticosteroid sprays for more comprehensive allergic rhinitis management, under medical guidance.
Allergic Rhinitis Medicines
Antihistamines
Leukotriene Receptor Antagonists
FAQs
Q1.
It's used to treat allergic rhinitis and hives, particularly when symptoms are more significant or when coexisting mild asthma-like symptoms are present.
Q2.
The two medicines work through different inflammatory pathways — histamine blockade and leukotriene blockade — so combining them can provide broader symptom control than either alone in appropriate patients.
Q3.
Bilastine's absorption is significantly reduced by food, particularly fruit juices, so it's generally recommended to be taken on an empty stomach.
Q4.
Yes, montelukast has been associated with mood or behaviour changes in some patients, including sleep disturbances or anxiety; any new or worsening symptoms should be reported to a doctor.
Q5.
Bilastine is largely non-sedating at standard doses, making this combination generally well tolerated from a sedation standpoint compared with older antihistamines.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






